Results 111 to 120 of about 74,841 (314)

Save the Bladder: Continent Urinary Diversion as Best Practice for Patients With Refractory Neurogenic Lower Urinary Tract Dysfunction

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Refractory neurogenic lower urinary tract dysfunction presents an obstinate clinical problem. For patients who fail nonsurgical measures, we advocate for bladder‐sparing, continent urinary diversion as the optimal approach to management.
Brian W. Chao, Sean P. Elliott
wiley   +1 more source

Recombinant synthesis and immunological characterization of single-domain antibodies against botulinum neurotoxin serotype A and B

Tạp chí Kiểm nghiệm và An toàn thực phẩm
Nanobodies which are single-domain antibodies derived from the Variable Heavy domain of Heavy-chain-only antibodies (VHHs) found in camels and sharks, represent a novel approach for enhancing the detection and neutralization of food toxins.
Luong Trung Hieu, Bui Thi Thu Hoai, Phan Thi Thanh Thuy, Nguyen Le Duc Hai, Nguyen Thi Anh Nguyet, Pham Bao Yen, Nguyen Thi Hong Loan, Phan Tuan Nghia, Nguyen Thanh Trung, Le Phuong Linh, Trinh Van Toan, Le Thi Hong Nhung   +11 more
doaj   +1 more source

A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication

Human Vaccines & Immunotherapeutics, 2018
Botulinum neurotoxins (BoNTs) are the most potent toxins to mammals. A toxoid vaccine was previously used for prevention of botulinum intoxication; however, this vaccine is no longer available. Currently, no approved botulinum vaccines are available from
Chi Ho Yu, Dong Hyun Song, Jun Young Choi, Hae Eun Joe, Woo Hyeon Jeong, Gyeung Haeng Hur, Young Kee Shin, Seong Tae Jeong   +7 more
doaj   +1 more source

Botulinum toxin type-A in the treatment of glabellar lines

, 2009
Leslie Winter1, Jeffrey Spiegel21Department of Otolaryngology, Boston Medical Center, Boston, MA, USA; 2Chief, Division of Facial Plastic Surgery Boston Medical Center Boston, MA, USAAbstract: The current literature and state of the art on use of ...
Leslie Winter, Jeffrey Spiegel
core  

“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan, Alyssa Kobayashi, Zhina Sadeghi   +2 more
wiley   +1 more source

Säilöntäaineiden vaikutus Clostridium botulinum tyyppi E:n kasvuun kirjolohen mädissä

, 2001
Clostridium botulinum on anaerobinen, gram-positiivinen, itiöitä muodostava sauvabakteeri, joka tuottaa voimakasta neurotoksiinia kasvunsa aikana. Botulinumneurotoksiinia tuottavat C.
Malk, Sini
core  

Neuropsychiatric‐Led Presentation of Late‐Onset Parkin‐Related Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Sarah Fullam, Shane Lyons, Martha Finnegan, Richard Walsh, Sean O'Dowd   +4 more
wiley   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

Clostridium botulinum tyyppi E:n lääkeaineherkkyys ja tyyppi E:lle selektiivisen elatusaineen kehittäminen

, 1997
Clostridium botulinum on yleinen bakteeri maaperässä ja vesistöissä. Se kasvaa anaerobisesti, eli se on erittäin potentiaalinen pilaaja säilykkeissä ja tyhjiöpakatuissa tuotteissa.
Jankola, Heidi
core  

Mirabegron and Intradetrusor Onabotulinumtoxina for Overactive Bladder in Parkinson's Disease: A Systematic Review and Meta‐Analysis

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad, Raiyana Nuha, Shehab Khashaba, David Gillatt, Simon J. G. Lewis   +4 more
wiley   +1 more source